Rare diseases
Investigational molecules
Locations
379 conditions with trials, the busiest first
1 291 trials across Europe, recruiting first
Study of AZD6793 tablets to reduce flare-ups in adults with moderate to very severe chronic obstructive pulmonary disease (COPD)
BulgariaStudy of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis
AustriaStudy on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer
BelgiumStudy on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen
BelgiumStudy comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression
BelgiumTitle: Study of tianeptine effectiveness in treating cognitive symptoms (brain fog) in patients who have recovered from COVID-19
PolandStudy of IPH5201 and Durvalumab for Pre- and Post-Surgery Treatment in Patients with Early-Stage Non-Small Cell Lung Cancer
FranceStudy on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids
BelgiumStudy on the Effects of Budesonide, Glycopyrronium, and Formoterol Fumarate for Patients with Chronic Obstructive Pulmonary Disease (COPD)
AustriaStudy of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
AustriaAdjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC
AustriaA study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer
FranceThe therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
